UTHR biotech catalysts & pipeline

UNITED THERAPEUTICS CORP · Data as of 2026-09-08

Upcoming catalysts

ralinepag DPI — IND submission

2026

We believe that these submissions, accompanied by our planned filings later this year – an IND application for ralinepag DPI and an NDA for treprostinil SMI – may herald an opportunity for a quantum increase in our growth by the end of the decade.

Source filing

treprostinil SMI — NDA/BLA submission

2026

We believe that these submissions, accompanied by our planned filings later this year – an IND application for ralinepag DPI and an NDA for treprostinil SMI – may herald an opportunity for a quantum increase in our growth by the end of the decade.

Source filing

Nebulized Tyvaso (treprostinil) — NDA/BLA submission

Late 2026

We intend to use the data from both the TETON-2 and TETON-1 studies to support a supplemental NDA ( sNDA ) to the FDA to add IPF to the labeled indications for Nebulized Tyvaso, which we plan to submit by the end of summer 2026.

Source filing

Nebulized Tyvaso (treprostinil) — Regulatory decision

By next year

By next year, we expect potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH, two potentially transformative, multi-billion-dollar catalysts that could significantly enhance our growth profile.

Source filing

ralinepag — Regulatory decision

By next year

By next year, we expect potential approvals for Nebulized Tyvaso in IPF and ralinepag tablets in PAH, two potentially transformative, multi-billion-dollar catalysts that could significantly enhance our growth profile.

Source filing

Explore the free biotech catalyst calendar